Eli Lilly & Co., a leading player in the pharmaceutical industry, has announced its intention to acquire Boston-based Kelonia Therapeutics for a minimum of $3.25 billion. This strategic move reflects Lilly’s ongoing commitment to expanding its capabilities in gene therapy, particularly in the realm of blood cancer treatments.
Innovative Treatment Approach
The acquisition will provide Lilly with access to KLN-1010, a promising therapy that modifies a patient’s immune cells to target cancer without the need for surgical removal. This revolutionary approach utilizes CAR-T technology, which reprograms immune cells to effectively combat cancer cells.
Jacob Van Naarden, executive vice president and president of Lilly Oncology and head of corporate business development, expressed optimism about KLN-1010’s potential. He highlighted that early clinical data offers strong encouragement for treating multiple myeloma, alongside validating Kelonia’s innovative platform.
Expansion of Cell Therapy Applications
Kelonia’s CEO, Kevin Friedman, elaborated on the partnership’s goals, stating that it aims to expand the application of cell therapies beyond the current CAR-T landscape. The collaboration is expected to pave the way for treating a diverse array of cancers and other diseases, enhancing the therapeutic options available to patients.
Financial Details of the Deal
Lilly’s acquisition will involve an immediate payment of $3.25 billion in cash to Kelonia. However, the total deal could escalate to $7 billion if Kelonia meets specific clinical and commercial milestones. With 62 employees, the majority of whom are situated in Boston, Kelonia stands to benefit significantly from Lilly’s extensive resources.
Lilly’s Recent Acquisitions
This acquisition is part of a broader strategy by Lilly, which has been actively investing in the biotechnology sector in the Boston area. The Kelonia deal, expected to close in the latter half of 2026, will be Lilly’s third acquisition of a Massachusetts biotech company this year.
Earlier in February, Lilly announced plans to purchase Orna Therapeutics for up to $2.4 billion. Orna is focused on developing cell therapies that harness a patient’s own cells without extraction, aiming to address autoimmune diseases through CAR-T technology.
In March, Lilly revealed its acquisition of Centessa Pharmaceuticals, a company specializing in narcolepsy treatments, in a deal valued at approximately $6.3 billion. These acquisitions illustrate Lilly’s aggressive growth strategy in the biotech landscape.
Strategic Partnerships in Biotech
In addition to acquisitions, Lilly has forged several partnerships with local biotech firms to develop new treatments for various medical conditions. Collaborating with Nimbus Therapeutics, Lilly aims to innovate an oral obesity treatment, with Nimbus poised to receive $55 million initially, and potentially up to $1.3 billion based on developmental and sales milestones.
Moreover, Lilly is partnering with Repertoire Immune Medicines to create therapies for autoimmune diseases. This collaboration entails an upfront investment of $85 million, with a total potential of $1.84 billion as Repertoire develops up to three drug candidates.
Investment in Research and Development
Lilly’s commitment to innovation is further demonstrated by its recent establishment of a $700 million research and development center in Boston’s Fort Point neighborhood. The facility is anticipated to employ around 500 workers, emphasizing Lilly’s dedication to advancing medical research and its role in the local biotech ecosystem.
In summary, Eli Lilly & Co. is solidifying its position in the biotechnology sector through strategic acquisitions and partnerships. The acquisition of Kelonia Therapeutics not only enhances Lilly’s therapeutic portfolio but also aligns with its vision to innovate within the field of gene therapy. As the company continues to invest in research and development, it is set to play a pivotal role in the future of healthcare.
- Eli Lilly acquires Kelonia Therapeutics for $3.25 billion.
- KLN-1010 offers a novel CAR-T therapy for blood cancer.
- Lilly’s Boston acquisitions underline its commitment to biotech innovation.
- Strategic partnerships are enhancing Lilly’s treatment development pipeline.
- A new R&D center in Boston signifies Lilly’s long-term investment in the region.
Read more → www.bostonglobe.com